Retatrutide (LY3437943) is an investigational synthetic peptide developed by Eli Lilly as a triple agonist. It simultaneously activates three key hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This multi-pathway approach builds on the success of dual agonists like tirzepatide (Mounjaro/Zepbound) by adding glucagon receptor activation, which may enhance energy expenditure, fat burning, and metabolic rate while promoting satiety and improving glucose control.
Brief History
Retatrutide emerged from Eli Lilly’s research into incretin-based therapies for obesity and type 2 diabetes. Early development focused on creating a single peptide with balanced agonism across the three receptors (strongest at GIP, followed by GLP-1 and glucagon). Phase 2 trials (published in the New England Journal of Medicine, 2023) demonstrated impressive results in adults with obesity. Phase 3 trials (TRIUMPH program) are ongoing or recently reported as of 2026, evaluating it for weight loss, diabetes, sleep apnea, osteoarthritis, and other metabolic conditions. It remains investigational/not FDA-approved for general use and is often accessed via research or compounding channels in biohacking contexts.
Key Benefits
Clinical data show dose-dependent effects:
- Substantial weight loss: Up to ~24% body weight reduction at 48 weeks (12 mg dose) in Phase 2, with Phase 3 extensions showing ~28-30% loss (~70 lbs average) over longer periods. Many participants achieve ≥15-30% loss.
- Metabolic improvements: Better blood sugar control (reduced HbA1c), liver fat reduction (steatosis), and favorable changes in lipids, blood pressure, and inflammation markers.
- Appetite and energy regulation: Strong reduction in hunger/”food noise,” slower gastric emptying, and potential increases in energy expenditure via glucagon action.
- Additional potential: Improvements in cardiovascular risk factors, possible muscle-sparing effects when combined with resistance training/protein intake, and benefits for conditions like OSA or knee pain in ongoing studies.
Risks and Side Effects
As with other incretin mimetics, gastrointestinal (GI) issues are most common and dose-related: nausea, diarrhea, vomiting, constipation (often mild-moderate, improving with time or slower titration). Other effects include increased heart rate (peaks then declines), potential HRV changes, fatigue during adaptation, and rare risks like gallbladder issues or pancreatitis (class effects). Muscle loss is a concern with rapid weight loss—prioritize strength training and adequate protein. Long-term safety data are still emerging; it is not suitable for everyone (e.g., history of medullary thyroid cancer, certain GI disorders, or pregnancy).
Beginner Dosing Schedule
Retatrutide is administered as a once-weekly subcutaneous injection (typically in the abdomen, thigh, or arm). Start low and go slow to minimize GI side effects—titration every 4 weeks is standard. A conservative beginner protocol for research/compounded use (adjust based on tolerance and provider guidance):
- Weeks 1–4: 0.5–1 mg once weekly (lowest starting dose for sensitivity).
- Weeks 5–8: 1–2 mg once weekly.
- Weeks 9–12: 2–4 mg once weekly.
- Maintenance: Escalate gradually toward 4–8 mg (or up to 12 mg in trials) if tolerated and needed for goals. Many see strong results at lower maintenance doses.
Tips: Inject consistently (e.g., same day/time). Stay hydrated, eat smaller nutrient-dense meals (high protein), and consider electrolytes or anti-nausea strategies initially. Track weight, body composition, HRV, fasting glucose, and side effects. Combine with resistance training, Mediterranean-style diet, and sleep optimization for best biohacking outcomes. Reassess every 4–8 weeks with your coach or clinician.
Retatrutide represents an exciting evolution in peptide-based metabolic tools, but success depends on personalized use, lifestyle support, and careful monitoring. Discuss with your healthcare provider to determine if it aligns with your health goals and to obtain proper sourcing/oversight. This is for educational purposes only.
Important Disclaimer: This document is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational compound and should only be used under the direct supervision of a qualified healthcare provider. Individual responses vary, and proper medical evaluation, monitoring, and personalized guidance are essential before considering any peptide or biohacking intervention. Always consult your physician or licensed medical professional regarding your specific health situation, risks, benefits, and any potential interactions.